

LAW OFFICES
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
ARLINGTON COURTHOUSE PLAZA I
SUITE 1400
2200 CLARENDON BOULEVARD
ARLINGTON, VIRGINIA 22101

TELEPHONE: (703) 243-6333
EMAIL: mail@mwzb.com
FAX: (703) 243-6410

Atty's Docket No. BAYER 12P1

Applicant(s) : Jacques Dumas et al.

For : INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL
SUBSTITUTED HETEROCYCLIC UREAS

Assistant Commissioner
for Patents
Washington, D.C. 20231

SUBMISSION OF APPLICATION UNDER 37 C.F.R. §1.53(f)

Sir:

Herewith is the above-identified application for Letters Patent including:

Applicant(s) Name(s) : Jacques DUMAS
Khire UDAY
Timothy Bruno LOWINGER
Bernard RIEDL
William J. SCOTT
Roger A. SMITH
Jill E. WOOD
Holia HATOUM-MOKDADD
Jeffrey JOHNSON
Aniko REDMAN
Robert SIBLEY

Assignee (by unrecorded assignment) :

Pages of Application: Specification - 45
Claims - 8
Abstract - 1
Sheets of Drawings -

Adjustment date: 01/25/1999 PWILSON
01/05/1999 SSANDORA 00000043-08995751 IS ATTACHED.
01 FC:114 -150.00 CR

- ☐ Preliminary Amendment
☐ Information Disclosure Statement
☒ The benefit under 35 U.S.C. §119 is claimed of the filing date of:


U.S. Provisional Application BAYER 12 P1, filed December 22, 1998.

Repln. Ref: ☐ A certified copy of the priority document(s) is attached.

DOI:133402 Name/Number:08995751
FC: 704 \$150.00 CR

Respectfully submitted,

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

By: 
Richard J. Traverso, Registration No. 30,595
Attorney for Applicant(s)

Filed: December 22, 1998
K:\PAT\Bayer\12\Rule53 wpd

RECEIVED

FEB 2 1999

RECEIVED MAIN EXHIBIT SERVICE CENTER

JUL 0 1 1999

TECH CENTER 1600/2900

RECEIVED

JUL 1 1999

GROUP 1700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

12/22/98
1c408 U.S. PTO

In re application of :

Jacques Dumas et al. :

Serial No.: 08/995,751 :

Filed: December 22, 1997 :

Examiner: T. Criares

Group Art Unit: 1614

RECEIVED

FEB 2 1999

INTELLECTUAL
PROPERTY
SERVICE CENTER

For: INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL
SUBSTITUTED HETEROCYCLIC UREAS

Petition for Conversion to a Provisional Application

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


It is hereby requested that the above-identified application be converted to a
provisional application in accordance with 37 C.F.R. 1.53(b)(2)(ii). Attached is the fee of
\$150.00 set forth in 37 C.F.R. 1.17(q).

Respectfully submitted,

RECEIVED

JUL 1 1999

GROUP 1700


Richard J. Traverso
Registration No. 30,595
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
(703) 812-5310
E-mail address: traverso@mwzb.com

Filed: December 22, 1998

RJT/maa
K:\PAT\Bayer\12\USto PROV.wpd

10

10

15

15

20

20

25

30

to have cytokine inhibitory activity both *in vitro* and *in vivo*. The isolated enzymes, CSBP-1 and -2 (CSAID binding protein 1 and 2) have been cloned and expressed. A murine homologue for CSBP-2, p38, has also been reported (Han et al. *Science* 1994, 265, 808).

5

Early studies suggested that CSAIDs function by interfering with m-RNA translational events during cytokine biosynthesis. Inhibition of p38 has been shown to inhibit both cytokine production (eg., $\text{TNF}\alpha$, IL-1, IL-6, IL-8) and proteolytic enzyme production (eg., MMP-1, MMP-3) *in vitro* and/or *in vivo*.

10

Clinical studies have linked $\text{TNF}\alpha$ production and/or signaling to a number of diseases including rheumatoid arthritis (Maini. *J. Royal Coll. Physicians London* 1996, 30, 344). In addition, excessive levels of $\text{TNF}\alpha$ have been implicated in a wide variety of inflammatory and/or immunomodulatory diseases, including acute
 15 rheumatic fever (Yegin et al. *Lancet* 1997, 349, 170), bone resorption (Pacifci et al. *J. Clin. Endocrinol. Metabol.* 1997, 82, 29), postmenopausal osteoporosis (Pacifci et al. *J. Bone Mineral Res.* 1996, 11, 1043), sepsis (Blackwell et al. *Br. J. Anaesth.* 1996, 77, 110), gram negative sepsis (Debets et al. *Prog. Clin. Biol. Res.* 1989, 308, 463), septic shock (Tracey et al. *Nature* 1987, 330, 662; Girardin et al. *New England*
 20 *J. Med.* 1988, 319, 397), endotoxic shock (Beutler et al. *Science* 1985, 229, 869; Ashkenasi et al. *Proc. Nat'l. Acad. Sci. USA* 1991, 88, 10535), toxic shock syndrome, (Saha et al. *J. Immunol.* 1996, 157, 3869; Lina et al. *FEMS Immunol. Med. Microbiol.* 1996, 13, 81), systemic inflammatory response syndrome (Anon. *Crit. Care Med.* 1992, 20, 864), inflammatory bowel diseases (Stokkers et al. *J. Inflamm.* 1995-6, 47,
 25 97) including Crohn's disease (van Deventer et al. *Aliment. Pharmacol. Therapeu.* 1996, 10 (Suppl. 2), 107; van Dullemen et al. *Gastroenterology* 1995, 109, 129) and ulcerative colitis (Masuda et al. *J. Clin. Lab. Immunol.* 1995, 46, 111), Jarisch-Herxheimer reactions (Fekade et al. *New England J. Med.* 1996, 335, 311), asthma (Amrani et al. *Rev. Malad. Respir.* 1996, 13, 539), adult respiratory distress syndrome
 30 (Roten et al. *Am. Rev. Respir. Dis.* 1991, 143, 590; Suter et al. *Am. Rev. Respir. Dis.* 1992, 145, 1016), acute pulmonary fibrotic diseases (Pan et al. *Pathol. Int.* 1996, 46,

- 91), pulmonary sarcoidosis (Ishioka et al. *Sarcoidosis Vasculitis Diffuse Lung Dis.* 1996, 13, 139), allergic respiratory diseases (Casale et al. *Am. J. Respir. Cell Mol. Biol.* 1996, 15, 35), silicosis (Gossart et al. *J. Immunol.* 1996, 156, 1540; Vanhee et al. *Eur. Respir. J.* 1995, 8, 834), coal worker's pneumoconiosis (Borm et al. *Am. Rev. Respir. Dis.* 1988, 138, 1589), alveolar injury (Horinouchi et al. *Am. J. Respir. Cell Mol. Biol.* 1996, 14, 1044), hepatic failure (Gantner et al. *J. Pharmacol. Exp. Therap.* 1997, 280, 53), liver disease during acute inflammation (Kim et al. *J. Biol. Chem.* 1997, 272, 1402), severe alcoholic hepatitis (Bird et al. *Ann. Intern. Med.* 1990, 112, 917), malaria (Grau et al. *Immunol. Rev.* 1989, 112, 49; Taverne et al. *Parasitol. Today* 1996, 12, 290) including *Plasmodium falciparum* malaria (Perlmann et al. *Infect. Immunit.* 1997, 65, 116) and cerebral malaria (Rudin et al. *Am. J. Pathol.* 1997, 150, 257), non-insulin-dependent diabetes mellitus (NIDDM; Stephens et al. *J. Biol. Chem.* 1997, 272, 971; Ofei et al. *Diabetes* 1996, 45, 881), congestive heart failure (Doyama et al. *Int. J. Cardiol.* 1996, 54, 217; McMurray et al. *Br. Heart J.* 1991, 66, 356), damage following heart disease (Malkiel et al. *Mol. Med. Today* 1996, 2, 336), atherosclerosis (Parums et al. *J. Pathol.* 1996, 179, A46), Alzheimer's disease (Fagarasan et al. *Brain Res.* 1996, 723, 231; Aisen et al. *Gerontology* 1997, 43, 143), acute encephalitis (Ichiyama et al. *J. Neurol.* 1996, 243, 457), brain injury (Cannon et al. *Crit. Care Med.* 1992, 20, 1414; Hansbrough et al. *Surg. Clin. N. Am.* 1987, 67, 69; Marano et al. *Surg. Gynecol. Obstetr.* 1990, 170, 32), multiple sclerosis (M.S.; Coyle. *Adv. Neuroimmunol.* 1996, 6, 143; Matusевич et al. *J. Neuroimmunol.* 1996, 66, 115) including demyelination and oligodendrocyte loss in multiple sclerosis (Brosnan et al. *Brain Pathol.* 1996, 6, 243), advanced cancer (MucWierzgon et al. *J. Biol. Regulators Homeostatic Agents* 1996, 10, 25), lymphoid malignancies (Levy et al. *Crit. Rev. Immunol.* 1996, 16, 31), pancreatitis (Exley et al. *Gut* 1992, 33, 1126) including systemic complications in acute pancreatitis (McKay et al. *Br. J. Surg.* 1996, 83, 919), impaired wound healing in infection inflammation and cancer (Buck et al. *Am. J. Pathol.* 1996, 149, 195), myelodysplastic syndromes (Raza et al. *Int. J. Hematol.* 1996, 63, 265), systemic lupus erythematosus (Maury et al. *Arthritis Rheum.* 1989, 32, 146), biliary cirrhosis (Miller et al. *Am. J. Gastroenterolog.* 1992, 87, 465), bowel necrosis (Sun et al. *J. Clin. Invest.* 1988, 81,

- 1328), psoriasis (Christophers. *Austr. J. Dermatol.* 1996, 37, S4), radiation injury (Redlich et al. *J. Immunol.* 1996, 157, 1705), and toxicity following administration of monoclonal antibodies such as OKT3 (Brod et al. *Neurology* 1996, 46, 1633). TNF α levels have also been related to host-versus-graft reactions (Piguet et al. *Immunol. Ser.* 1992, 56, 409) including ischemia reperfusion injury (Colletti et al. *J. Clin. Invest.* 1989, 85, 1333) and allograft rejections including those of the kidney (Maury et al. *J. Exp. Med.* 1987, 166, 1132), liver (Imagawa et al. *Transplantation* 1990, 50, 219), heart (Bolling et al. *Transplantation* 1992, 53, 283), and skin (Stevens et al. *Transplant. Proc.* 1990, 22, 1924), lung allograft rejection (Grossman et al. *Immunol. Allergy Clin. N. Am.* 1989, 9, 153) including chronic lung allograft rejection (obliterative bronchitis; LoCicero et al. *J. Thorac. Cardiovasc. Surg.* 1990, 99, 1059), as well as complications due to total hip replacement (Cirino et al. *Life Sci.* 1996, 59, 86). TNF α has also been linked to infectious diseases (review: Beutler et al. *Crit. Care Med.* 1993, 21, 5423; Degre. *Biotherapy* 1996, 8, 219) including tuberculosis (Rook et al. *Med. Malad. Infect.* 1996, 26, 904), *Helicobacter pylori* infection during peptic ulcer disease (Beales et al. *Gastroenterology* 1997, 112, 136), Chaga's disease resulting from *Trypanosoma cruzi* infection (Chandrasekar et al. *Biochem. Biophys. Res. Commun.* 1996, 223, 365), effects of Shiga-like toxin resulting from *E. coli* infection (Harel et al. *J. Clin. Invest.* 1992, 56, 40), the effects of enterotoxin A resulting from *Staphylococcus* infection (Fischer et al. *J. Immunol.* 1990, 144, 4663), meningococcal infection (Waage et al. *Lancet* 1987, 355; Ossege et al. *J. Neurolog. Sci.* 1996, 144, 1), and infections from *Borrelia burgdorferi* (Brandt et al. *Infect. Immunol.* 1990, 58, 983), *Treponema pallidum* (Chamberlin et al. *Infect. Immunol.* 1989, 57, 2872), cytomegalovirus (CMV; Geist et al. *Am. J. Respir. Cell Mol. Biol.* 1997, 16, 31), influenza virus (Beutler et al. *Clin. Res.* 1986, 34, 491a), Sendai virus (Goldfield et al. *Proc. Nat'l. Acad. Sci. USA* 1989, 87, 1490), Theiler's encephalomyelitis virus (Sierra et al. *Immunology* 1993, 78, 399), and the human immunodeficiency virus (HIV; Poli. *Proc. Nat'l. Acad. Sci. USA* 1990, 87, 782; Vyakaram et al. *AIDS* 1990, 4, 21; Badley et al. *J. Exp. Med.* 1997, 185, 55).

Because inhibition of p38 leads to inhibition of TNF α production, p38 inhibitors will be useful in treatment of the above listed diseases.

A number of diseases are thought to be mediated by excess or undesired matrix-destroying metalloprotease (MMP) activity or by an imbalance in the ratio of the
 5 MMPs to the tissue inhibitors of metalloproteinases (TIMPs). These include osteoarthritis (Woessner et al. *J. Biol. Chem.* **1984**, 259, 3633), rheumatoid arthritis (Mullins et al. *Biochim. Biophys. Acta* **1983**, 695, 117; Woolley et al. *Arthritis Rheum.* **1977**, 20, 1231; Gravallesse et al. *Arthritis Rheum.* **1991**, 34, 1076), septic
 10 arthritis (Williams et al. *Arthritis Rheum.* **1990**, 33, 533), tumor metastasis (Reich et al. *Cancer Res.* **1988**, 48, 3307; Matrisian et al. *Proc. Nat'l. Acad. Sci., USA* **1986**, 83, 9413), periodontal diseases (Overall et al. *J. Periodontal Res.* **1987**, 22, 81), corneal ulceration (Burns et al. *Invest. Ophthalmol. Vis. Sci.* **1989**, 30, 1569), proteinuria (Baricos et al. *Biochem. J.* **1988**, 254, 609), coronary thrombosis from atherosclerotic
 15 plaque rupture (Henney et al. *Proc. Nat'l. Acad. Sci., USA* **1991**, 88, 8154), aneurysmal aortic disease (Vine et al. *Clin. Sci.* **1991**, 81, 233), birth control (Woessner et al. *Steroids* **1989**, 54, 491), dystrophic epidermolysis bullosa (Kronberger et al. *J. Invest. Dermatol.* **1982**, 79, 208), degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero
 20 mandibular joint disease, and demyelating diseases of the nervous system (Chantry et al. *J. Neurochem.* **1988**, 50, 688).

Because inhibition of p38 leads to inhibition of MMP production, p38 inhibitors will be useful in treatment of the above listed diseases.

25

Inhibitors of p38 are active in animal models of TNF α production, including a murine lipopolysaccharide (LPS) model of TNF α production. Inhibitors of p38 are active in a number of standard animal models of inflammatory diseases, including carrageenan-induced edema in the rat paw, arachadonic acid-induced edema in the rat paw,
 30 arachadonic acid-induced peritonitis in the mouse, fetal rat long bone resorption, murine type II collagen-induced arthritis, and Freund's adjuvant-induced arthritis in

the rat. Thus, inhibitors of p38 will be useful in treating diseases mediated by one or more of the above-mentioned cytokines and/or proteolytic enzymes.

The need for new therapies is especially important in the case of arthritic diseases.

5 The primary disabling effect of osteoarthritis, rheumatoid arthritis and septic arthritis is the progressive loss of articular cartilage and thereby normal joint function. No marketed pharmaceutical agent is able to prevent or slow this cartilage loss, although nonsteroidal antiinflammatory drugs (NSAIDs) have been given to control pain and swelling. The end result of these diseases is total loss of joint function which is only

10 treatable by joint replacement surgery. P38 inhibitors will halt or reverse the progression of cartilage loss and obviate or delay surgical intervention.

Several patents have appeared claiming polyarylimidazoles and/or compounds containing polyarylimidazoles as inhibitors of p38 (for example, Lee et al. WO

15 95/07922; Adams et al. WO 95/02591; Adams et al. WO 95/13067; Adams et al. WO 95/31451). It has been reported that arylimidazoles complex to the ferric form of cytochrome P450_{cam} (Harris et al. *Mol. Eng.* 1995, 5, 143, and references therein), causing concern that these compounds may display structure-related toxicity (Howard-Martin et al. *Toxicol. Pathol.* 1987, 15, 369). Therefore, there remains a

20 need for improved p38 inhibitors.

Summary of the Invention

This invention provides compounds, generally described as aryl ureas, including both aryl and heteroaryl analogues, which inhibit p38 mediated events and thus inhibit the

25 production of cytokines (such as TNF α , IL-1 and IL-8) and proteolytic enzymes (such as MMP-1 and MMP-3). The invention also provides a method of treating a cytokine mediated disease state in humans or mammals, wherein the cytokine is one whose production is affected by p38. Examples of such cytokines include, but are not limited to TNF α , IL-1 and IL-8. The invention also provides a method of treating a

30 protease mediated disease state in humans or mammals, wherein the protease is one

whose production is affected by p38. Examples of such proteases include, but are not limited to collagenase (MMP-1) and stromelysin (MMP-3).

Accordingly, these compounds are useful therapeutic agents for such acute and chronic inflammatory and/or immunomodulatory diseases as rheumatoid arthritis, osteoarthritis, septic arthritis, rheumatic fever, bone resorption, postmenopausal osteoporosis, sepsis, gram negative sepsis, septic shock, endotoxic shock, toxic shock syndrome, systemic inflammatory response syndrome, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, Jarisch-Herxheimer reactions, asthma, adult respiratory distress syndrome, acute pulmonary fibrotic diseases, pulmonary sarcoidosis, allergic respiratory diseases, silicosis, coal worker's pneumoconiosis, alveolar injury, hepatic failure, liver disease during acute inflammation, severe alcoholic hepatitis, malaria including Plasmodium falciparum malaria and cerebral malaria, non-insulin-dependent diabetes mellitus (NIDDM), congestive heart failure, damage following heart disease, atherosclerosis, Alzheimer's disease, acute encephalitis, brain injury, multiple sclerosis including demyelination and oligiodendrocyte loss in multiple sclerosis, advanced cancer, lymphoid malignancies, tumor metastasis, pancreatitis, including systemic complications in acute pancreatitis, impaired wound healing in infection, inflammation and cancer, periodontal diseases, corneal ulceration, proteinuria, myelodysplastic syndromes, systemic lupus erythematosus, biliary cirrhosis, bowel necrosis, psoriasis, radiation injury, toxicity following administration of monoclonal antibodies such as OKT3, host-versus-graft reactions including ischemia reperfusion injury and allograft rejections including kidney, liver, heart, and skin allograft rejections, lung allograft rejection including chronic lung allograft rejection (obliterative bronchitis) as well as complications due to total hip replacement, and infectious diseases including tuberculosis, Helicobacter pylori infection during peptic ulcer disease, Chaga's disease resulting from Trypanosoma cruzi infection, effects of Shiga-like toxin resulting from E. coli infection, effects of enterotoxin A resulting from Staphylococcus infection, meningococcal infection, and infections from Borrelia burgdorferi, Treponema

pallidum, cytomegalovirus, influenza virus, Theiler's encephalomyelitis virus, and the human immunodeficiency virus (HIV).

The present invention, therefore, provides compounds generally described as aryl ureas, including both aryl and heteroaryl analogues, which inhibit the p38 pathway. The invention also provides a method for treatment of p38-mediated disease states in humans or mammals, e.g., disease states mediated by one or more cytokines or proteolytic enzymes produced and/or activated by a p38 mediated process. Thus, the invention is directed to compounds and methods for the treatment of diseases mediated by p38 kinase comprising administering a compound of Formula I



wherein B is generally an unsubstituted or substituted, up to tricyclic, aryl or heteroaryl moiety with up to 30 carbon atoms with at least one 5 or 6 member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur. A is a heteroaryl moiety discussed in more detail below.

The aryl and heteroaryl moiety of B may contain separate cyclic structures and can include a combination of aryl, heteroaryl and cycloalkyl structures. The substituents for these aryl and heteroaryl moieties can vary widely and include halogen, hydrogen, hydrosulfide, cyano, nitro, amines and various carbon-based moieties, including those which contain one or more of sulfur, nitrogen, oxygen and/or halogen and are discussed more particularly below.

Suitable aryl and heteroaryl moieties for B of formula I include, but are not limited to aromatic ring structures containing 4-30 carbon atoms and 1-3 rings, at least one of which is a 5-6 member aromatic ring. One or more of these rings may have 1-4 carbon atoms replaced by oxygen, nitrogen and/or sulfur atoms.

Examples of suitable aromatic ring structures include phenyl, pyridinyl, naphthyl, pyrimidinyl, benzothiazolyl, quinoline, isoquinoline, phthalimidinyl and combinations thereof, such as diphenyl ether (phenyloxyphenyl), diphenyl thioether (phenylthiophenyl), phenylaminophenyl, phenylpyridinyl ether (pyridinyloxyphenyl),
 5 pyridinylmethylphenyl, phenylpyridinyl thioether (pyridinylthiophenyl), phenylbenzothiazolyl ether (benzothiazolyloxyphenyl), phenylbenzothiazolyl thioether (benzothiazolylthiophenyl), phenylpyrimidinyl ether, phenylquinoline thioether, phenylnaphthyl ether, pyridinylnaphthyl ether, pyridinylnaphthyl thioether, and phthalimidylmethylphenyl.

10 Examples of suitable heteroaryl groups include, but are not limited to, 5-12 carbon-atom aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by oxygen, nitrogen or sulfur atoms. Each ring typically has 3-7 atoms.

15 For example, B can be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2-
 20 or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,3,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothieryl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl,
 25 3-, 4-, 5- 6- or 7-benzisoxazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 4-, 5-, 6- or 7-benz-1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, 8- isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, or 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, or additionally optionally substituted phenyl, 2- or 3-thienyl, 1,3,4-thiadiazolyl, 3-pyrrolyl, 3-pyrazolyl,
 30 2-thiazolyl or 5-thiazolyl, etc. For example, B can be 4-methyl-phenyl, 5-methyl-2-

thienyl, 4-methyl-2-thienyl, 1-methyl-3-pyrryl, 1-methyl-3-pyrazolyl, 5-methyl-2-thiazolyl or 5-methyl-1,2,4-thiadiazol-2-yl.

Suitable alkyl groups and alkyl portions of groups, e.g., alkoxy, etc., throughout
5 include methyl, ethyl, propyl, butyl, etc., including all straight-chain and branched isomers such as isopropyl, isobutyl, *sec*-butyl, *tert*-butyl, etc.

Suitable aryl groups include, for example, phenyl and 1- and 2-naphthyl.

10 Suitable cycloalkyl groups include cyclopropyl, cyclobutyl, cyclohexyl, etc. The term "cycloalkyl", as used herein, refers to cyclic structures with or without alkyl substituents such that, for example, "C₄ cycloalkyl" includes methyl substituted cyclopropyl groups as well as cyclobutyl groups. The term "cycloalkyl also includes
15 saturated heterocycles.

Suitable halogens include F, Cl, Br, and/or I, from one to persubstitution (i.e., all H atoms on the group are replaced by halogen atom), being possible, mixed substitution of halogen atom types also being possible on a given moiety.

20 As indicated above, these ring systems can be unsubstituted or substituted by substituents such as halogen up to per-halosubstitution. Other suitable substituents for the moieties of B include alkyl, alkoxy, carboxy, cycloalkyl, aryl, heteroaryl, cyano, hydroxy and amine. These other substituents, generally referred to as X and X' herein, include -CN, -CO₂R⁵, -C(O)NR⁵R^{5'}, -C(O)R⁵, -NO₂, -OR⁵, -SR⁵, -NR⁵R^{5'},
25 -NR⁵C(O)OR^{5'}, -NR⁵C(O)R^{5'}, C₁-C₁₀ alkyl, C₂₋₁₀-alkenyl, C₁₋₁₀-alkoxy, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₇-C₂₄ alkaryl, C₃-C₁₃ heteroaryl, C₄-C₂₃ alkheteroaryl, substituted C₁-C₁₀ alkyl, substituted C₂₋₁₀-alkenyl, substituted C₁₋₁₀-alkoxy, substituted C₃-C₁₀ cycloalkyl, substituted C₄-C₂₃ alkheteroaryl and -Y-Ar.

30 Where a substituent, X or X', is a substituted group, it is preferably substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁵, -C(O)R⁵, -C(O)NR⁵R^{5'}, -OR⁵, -SR⁵, -NR⁵R^{5'}, -NO₂, -NR⁵C(O)R^{5'},

$-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$ and halogen up to per-halo substitution.


The moieties R^5 and $\text{R}^{5'}$ are preferably independently selected from H, $\text{C}_1\text{-C}_{10}$ alkyl, C_{2-10} -alkenyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_6\text{-C}_{14}$ aryl, $\text{C}_3\text{-C}_{13}$ heteroaryl, $\text{C}_7\text{-C}_{24}$ alkaryl, $\text{C}_4\text{-C}_{23}$ alkheteroaryl, up to per-halosubstituted $\text{C}_1\text{-C}_{10}$ alkyl, up to per-halosubstituted C_{2-10} -alkenyl, up to per-halosubstituted $\text{C}_3\text{-C}_{10}$ cycloalkyl, up to per-halosubstituted $\text{C}_6\text{-C}_{14}$ aryl and up to per-halosubstituted $\text{C}_3\text{-C}_{13}$ heteroaryl.


The bridging group Y is preferably $-\text{O}-$, $-\text{S}-$, $-\text{N}(\text{R}^5)-$, $-(\text{CH}_2)_m-$, $-\text{C}(\text{O})-$, $-\text{CH}(\text{OH})-$, $-\text{NR}^5\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$, $-\text{NR}^5\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NR}^5-$, $-(\text{CH}_2)_m\text{O}-$, $-(\text{CH}_2)_m\text{S}-$, $-(\text{CH}_2)_m\text{N}(\text{R}^5)-$, $-\text{O}(\text{CH}_2)_m-$, $-\text{CHX}^a$, $-\text{CX}^a_2-$, $-\text{S}-(\text{CH}_2)_m-$ and $-\text{N}(\text{R}^5)(\text{CH}_2)_m-$, where $m = 1-3$, and X^a is halogen.

The moiety Ar is preferably a 5-10 member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Z_{n1} , wherein $n1$ is 0 to 3.


Each Z substituent is preferably independently selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$, $-\text{C}(\text{O})-\text{NR}^5$, $-\text{NO}_2$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NR}^5\text{R}^{5'}$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$, $-\text{C}(\text{O})\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{R}^{5'}$, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_6\text{-C}_{14}$ aryl, $\text{C}_3\text{-C}_{13}$ heteroaryl, $\text{C}_7\text{-C}_{24}$ alkaryl, $\text{C}_4\text{-C}_{23}$ alkheteroaryl, substituted $\text{C}_1\text{-C}_{10}$ alkyl, substituted $\text{C}_3\text{-C}_{10}$ cycloalkyl, substituted $\text{C}_7\text{-C}_{24}$ alkaryl and substituted $\text{C}_4\text{-C}_{23}$ alkheteroaryl. If Z is a substituted group, it is substituted by the one or more substituents independently selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NO}_2$, $-\text{NR}^5\text{R}^{5'}$, $-\text{NR}^5\text{C}(\text{O})\text{R}^{5'}$ and $-\text{NR}^5\text{C}(\text{O})\text{OR}^{5'}$.

The aryl and heteroaryl moieties of B of Formula I are preferably selected from the group consisting of





5




and

;

- 10 which are unsubstituted or substituted by halogen, up to per-halosubstitution. X is as defined above and $n = 0-3$.

The aryl and heteroaryl moieties of B are more preferably of the formula:



15

wherein Y is selected from the group consisting of $-O-$, $-S-$, $-CH_2-$, $-SCH_2-$, $-CH_2S-$, $-CH(OH)-$, $-C(O)-$, $-CX^a_2$, $-CX^aH-$, $-CH_2O-$ and $-OCH_2-$ and X^a is halogen.


- 20 Q is a six member aromatic structure containing 0-2 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution and Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution. X, Z, n and $n1$ are as defined above and $s = 0$ or 1.

25

- In preferred embodiments, Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution and Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo substitution, or
- 30 $-Y-Q^1$ is phthalimidinyl substituted or unsubstituted by halogen up to per-halo

substitution. Z and X are preferably independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1 - C_{10} -alkyl or C_3 - C_{10} -cycloalkyl and R^7 is preferably selected from the group consisting of hydrogen, C_3 - C_{10} -alkyl, C_3 - C_6 -cycloalkyl and C_6 - C_{10} -aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

The heteroaryl moiety A of formula I is preferably selected from the group consisting of:



wherein R^1 is preferably selected from the group consisting of C_3 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, up to per-halosubstituted C_1 - C_{10} alkyl and up to per-halosubstituted C_3 - C_{10} cycloalkyl and R^2 is C_6 - C_{14} aryl, C_3 - C_{14} heteroaryl, substituted C_6 - C_{14} aryl or substituted C_3 - C_{14} heteroaryl.

Where R^2 is a substituted group, it is preferably substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and V_n , where $n = 0-3$.

Each V is preferably independently selected from the group consisting of $-CN$, $-OC(O)NR^5R^{5'}$, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-C(O)R^5$, $-NR^5C(O)OR^{5'}$, $-SO_2R^5$, $-SOR^5$, $-NR^5C(O)R^{5'}$, $-NO_2$, C_1 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, C_6 - C_{14} aryl, C_3 - C_{13} heteroaryl, C_7 - C_{24} alkaryl, C_4 - C_{24} alkheteroaryl, substituted C_1 - C_{10} alkyl, substituted C_3 - C_{10} cycloalkyl, substituted C_6 - C_{14} aryl, substituted C_3 - C_{13} heteroaryl, substituted C_7 - C_{24} alkaryl and substituted C_4 - C_{24} alkheteroaryl.

If V is a substituted group, it is preferably substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{R}^5$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NR}^5\text{C}(\text{O})\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^5$ and $-\text{NO}_2$.

5

The substituents R^5 and R^5 are preferably each independently selected from the group consisting of H, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_6\text{-C}_{14}$ aryl, $\text{C}_3\text{-C}_{13}$ heteroaryl, $\text{C}_7\text{-C}_{24}$ alkaryl, $\text{C}_4\text{-C}_{23}$ alkheteroaryl, up to per-halosubstituted $\text{C}_1\text{-C}_{10}$ alkyl, up to per-halosubstituted $\text{C}_3\text{-C}_{10}$ cycloalkyl, up to per-halosubstituted $\text{C}_6\text{-C}_{14}$ aryl and up to per-halosubstituted $\text{C}_3\text{-C}_{13}$ heteroaryl.

10

R^2 is more preferably substituted or unsubstituted phenyl or pyridinyl, where the substituents for R^2 are selected from the group consisting of halogen, up to per-halosubstitution and V_n^1 , wherein $n = 0\text{-}3$. Each V^1 is preferably independently selected from the group consisting of substituted and unsubstituted $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_6\text{-C}_{10}$ aryl, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{C}(\text{O})\text{-C}_{1-6}$ alkyl, $-\text{C}(\text{O})\text{N}(\text{C}_{1-6}\text{ alkyl})_2$, $-\text{C}(\text{O})\text{NH-C}_{1-6}$ alkyl, $-\text{O-C}_{1-6}$ alkyl, $-\text{NHC}(\text{O})\text{H}$, $-\text{NHC}(\text{O})\text{OH}$, $-\text{N}(\text{C}_{1-6}\text{ alkyl})$, $\text{C}(\text{O})\text{-C}_{1-6}$ alkyl, $-\text{N}(\text{C}_{1-6}\text{ alkyl})\text{C}(\text{O})\text{-C}_{1-6}$ alkyl, $-\text{OC}(\text{O})\text{NH-C}_6\text{-C}_{14}$ aryl, $-\text{NHC}(\text{O})\text{-C}_{1-6}$ alkyl, $-\text{OC}(\text{O})\text{NH-C-NHC}(\text{O})\text{O-C}_{1-6}$ alkyl, $-\text{S}(\text{O})\text{-C}_{1-6}$ alkyl and $-\text{SO}_2\text{-C}_{1-6}$ alkyl. Where V^1 is a substituted group, it is preferably substituted by one or more halogen, up to per-halosubstitution.

Most preferably, R^2 is selected from substituted and unsubstituted phenyl or pyridinyl groups, where the substituents are halogen and W_n ($n = 0\text{-}3$).

W is preferably selected from the group consisting of $-\text{NO}_2$, -C_{1-3} alkyl, $-\text{NH}(\text{O})\text{CH}_3$, $-\text{CF}_3$, $-\text{OCH}_3$, $-\text{F}$, $-\text{Cl}$, $-\text{NH}_2$, $-\text{OC}(\text{O})\text{NH}$ up to per-halosubstituted phenyl, $-\text{SO}_2\text{CH}_3$, pyridinyl, phenyl, up to per-halosubstituted phenyl and $\text{C}_1\text{-C}_6$ alkyl substituted phenyl.

The present invention is also directed to pharmaceutically acceptable salts of formula I. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid.

In addition, pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li^+ Na^+ or K^+), alkaline earth cations (e.g., Mg^{+2} , Ca^{+2} or Ba^{+2}), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations such as those arising from protonation or peralkylation of triethylamine, *N,N*-diethylamine, *N,N*-dicyclohexylamine, pyridine, *N,N*-dimethylaminopyridine (DMAP), 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).


A number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art. The present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess p38 kinase inhibitory activity.

The compounds of Formula I may be prepared by use of known chemical reactions and procedures. Nevertheless, the following general preparative methods are presented to aid one of skill in the art in synthesizing the inhibitors, with more detailed particular examples being presented in the experimental section describing the working examples.

General Preparative Methods


The compounds of Formula I may be prepared by the use of known chemical reactions and procedures, some from starting materials which are commercially available. Nevertheless, general preparative methods are provided below to aid one skilled in the art in synthesizing these compounds, with more detailed examples being provided in the Experimental section which follows.

Heterocyclic amines may be synthesized utilizing known methodology (Katritzky, et al. *Comprehensive Heterocyclic Chemistry*; Pergamon Press: Oxford, UK (1984). March. *Advanced Organic Chemistry*, 3rd Ed.; John Wiley: New York (1985)). For example, as shown in Scheme I, 5-aminopyrazoles substituted at the *N*-1 position with either aryl or heteroaryl moieties may be synthesized by the reaction of an α -cyanoketone (**2**) with the appropriate aryl- or heteroaryl hydrazine (**3**, R^2 =aryl or heteroaryl). Cyanoketone **2**, in turn, is available from the reaction of acetamidate ion with an appropriate acyl derivative, such as an ester, an acid halide, or an acid anhydride. In cases where the R^2 moiety offers suitable anion stabilization, 2-aryl- and 2-heteroarylfurans may be synthesized from a Mitsunobu reaction of cyanoketone **2** with alcohol **5**, followed by base catalyzed cyclization of enol ether **6** to give furylamine **7**.



Scheme I. Selected General Methods for Heterocyclic Amine Synthesis


Substituted anilines may be generated using standard methods (March. *Advanced Organic Chemistry*, 3rd Ed.; John Wiley: New York (1985). Larock. *Comprehensive Organic Transformations*; VCH Publishers: New York (1989)). As shown in Scheme II, aryl amines are commonly synthesized by reduction of nitroaryls using a metal catalyst, such as Ni, Pd, or Pt, and H₂ or a hydride transfer agent, such as formate, cyclohexadiene, or a borohydride (Rylander. *Hydrogenation Methods*; Academic Press: London, UK (1985)). Nitroaryls may also be directly reduced using a strong hydride source, such as LiAlH₄ (Seyden-Penne. *Reductions by the Alumino- and Borohydrides in Organic Synthesis*; VCH Publishers: New York (1991)), or using a zero valent metal, such as Fe, Sn or Ca, often in acidic media. Many methods exist for the synthesis of nitroaryls (March. *Advanced Organic Chemistry*, 3rd Ed.; John Wiley: New York (1985). Larock. *Comprehensive Organic Transformations*; VCH Publishers: New York (1989)).



Scheme II Reduction of Nitroaryls to Aryl Amines


Nitroaryls are commonly formed by electrophilic aromatic nitration using HNO_3 , or an alternative NO_2^+ source. Nitro aryls may be further elaborated prior to reduction.

5 Thus, nitroaryls substituted with



potential leaving groups (eg. F, Cl, Br, etc.) may undergo substitution reactions on treatment with nucleophiles, such as thiolate (exemplified in Scheme III) or phenoxide. Nitroaryls may also undergo Ullman-type coupling reactions (Scheme

10 III).




Scheme III Selected Nucleophilic Aromatic Substitution using Nitroaryls

As shown in Scheme IV, urea formation may involve reaction of a heteroaryl isocyanate (12) with an aryl amine (11). The heteroaryl isocyanate may be

15 synthesized from a heteroaryl amine by treatment with phosgene or a phosgene equivalent, such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl) carbonate (triphosgene), or N,N' -carbonyldiimidazole (CDI). The isocyanate may


also be derived from a heterocyclic carboxylic acid derivative, such as an ester, an acid halide or an anhydride by a Curtius-type rearrangement. Thus, reaction of acid derivative **16** with an azide source, followed by rearrangement affords the isocyanate. The corresponding carboxylic acid (**17**) may also be subjected to Curtius-type rearrangements using diphenylphosphoryl azide (DPPA) or a similar reagent. A urea may also be generated from the reaction of an aryl isocyanate (**15**) with a heterocyclic amine.



Scheme IV Selected Methods of Urea Formation (Het = heterocycle)

- Finally, ureas may be further manipulated using methods familiar to those skilled in the art. For example, 2-aryl and 2-heteroarylthienyl ureas are available from the corresponding 2-halothienyl urea through transition metal mediated cross coupling reactions (exemplified with 2-bromothiophene **25**, Scheme V). Thus, reaction of nitrile **20** with an α -thioacetate ester gives 5-substituted-3-amino-2-thiophenecarboxylate **21** (Ishizaki et al. JP 6025221). Decarboxylation of ester **21** may be achieved by protection of the amine, for example as the *tert*-butoxy (BOC) carbamate (**22**), followed by saponification and treatment with acid. When BOC protection is used, decarboxylation may be accompanied by deprotection giving the substituted 3-thiopheneammonium salt **23**. Alternatively, ammonium salt **23** may be directly generated through saponification of ester **21** followed by treatment with acid. Following urea formation as described above, bromination affords penultimate

halothiophene **25**. Palladium mediated cross coupling of thiophene **25** with an appropriate tributyl- or trimethyltin (R^2 = aryl or heteroaryl) then affords the desired 2-aryl- or 2-heteroarylthienyl urea.



5

Scheme V Synthesis and Interconversion of Ureas

The invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.

10

The compounds may be administered orally, topically, parenterally, by inhalation or spray or vaginally, rectally or sublingually in dosage unit formulations. The term 'administration by injection' includes intravenous, intramuscular, subcutaneous and

parenteral injections, as well as use of infusion techniques. Dermal administration may include topical application or transdermal administration. One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.

5

Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.

10

15

20

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

25

Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate,

30

polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, *p*-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.

The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, for example olive oil or arachis oil,

or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example
5 sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol,
10 propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

The compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug. These compositions can be prepared by mixing
15 the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperature and will therefore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.

20 Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien; "Transdermal Controlled Systemic Medications"; Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 3Mar94). For example, a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be
25 combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms. In addition, on treatment with emulsifying agents and water, a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.

Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane. Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.

Suitable penetration enhancing materials for transdermal delivery system are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C₈-C₁₈ fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C₈-C₁₈ fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diisopropyl sebacate, diisopropyl maleate, or diisopropyl fumarate. Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbide and diethyleneglycol monoethyl ether. Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C₈-C₁₈ fatty alcohols, saturated or unsaturated C₈-C₁₈ fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.

Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers,

styrenebutadiene copolymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.

5

For all regimens of use disclosed herein for compounds of Formula I, the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily rectal dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/Kg. The daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.

It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be understood, however, that the specific dose level for any given patient will depend upon a variety of factors, including, the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy. It will be further appreciated by one skilled in the art that the optimal course of treatment, ie, the mode of treatment and the daily number of doses of a compound of Formulae I or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment tests.

The entire disclosure of all applications, patents and publications cited above and below are hereby incorporated by reference, including provisional application (Attorney Docket Number BAYER 12V1), filed on December 22, 1997, as SN
5 08/995,751, and converted on December 22, 1998.

The following examples are for illustrative purposes only and are not intended, nor should they be construed to limit the invention in any way.

SECRET

EXAMPLES

All reactions were performed in flame-dried or oven-dried glassware under a positive pressure of dry argon or dry nitrogen, and were stirred magnetically unless otherwise indicated. Sensitive liquids and solutions were transferred via syringe or cannula, and introduced into reaction vessels through rubber septa. Unless otherwise stated, the term 'concentration under reduced pressure' refers to use of a Buchi rotary evaporator at approximately 15 mmHg.

All temperatures are reported uncorrected in degrees Celsius (°C). Unless otherwise indicated, all parts and percentages are by weight.

Commercial grade reagents and solvents were used without further purification. Thin-layer chromatography (TLC) was performed on Whatman® pre-coated glass-backed silica gel 60A F-254 250 µm plates. Visualization of plates was effected by one or more of the following techniques: (a) ultraviolet illumination, (b) exposure to iodine vapor, (c) immersion of the plate in a 10% solution of phosphomolybdic acid in ethanol followed by heating, (d) immersion of the plate in a cerium sulfate solution followed by heating, and/or (e) immersion of the plate in an acidic ethanol solution of 2,4-dinitrophenylhydrazine followed by heating. Column chromatography (flash chromatography) was performed using 230-400 mesh EM Science® silica gel.

Melting points (mp) were determined using a Thomas-Hoover melting point apparatus or a Mettler FP66 automated melting point apparatus and are uncorrected. Proton (¹H) nuclear magnetic resonance (NMR) spectra were measured with a General Electric GN-Omega 300 (300 MHz) spectrometer with either Me₄Si (δ 0.00) or residual protonated solvent (CHCl₃ δ 7.26; MeOH δ 3.30; DMSO δ 2.49) as standard. Carbon (¹³C) NMR spectra were measured with a General Electric GN-Omega 300 (75 MHz) spectrometer with solvent (CDCl₃ δ 77.0; MeOD-d₃; δ 49.0; DMSO-d₆ δ 39.5) as standard. Low resolution mass spectra (MS) and high resolution mass spectra (HRMS) were either obtained as electron impact (EI) mass spectra or as fast atom bombardment (FAB) mass spectra. Electron impact mass spectra (EI-MS) were

obtained with a Hewlett Packard 5989A mass spectrometer equipped with a Vacumetrics Desorption Chemical Ionization Probe for sample introduction. The ion source was maintained at 250 °C. Electron impact ionization was performed with electron energy of 70 eV and a trap current of 300 μ A. Liquid-cesium secondary ion mass spectra (FAB-MS), an updated version of fast atom bombardment were obtained using a Kratos Concept 1-H spectrometer. Chemical ionization mass spectra (CI-MS) were obtained using a Hewlett Packard MS-Engine (5989A) with methane as the reagent gas (1×10^{-4} torr to 2.5×10^{-4} torr). The direct insertion desorption chemical ionization (DCI) probe (Vacumetrics, Inc.) was ramped from 0-1.5 amps in 10 sec and held at 10 amps until all traces of the sample disappeared (~1-2 min). Spectra were scanned from 50-800 amu at 2 sec per scan. HPLC - electrospray mass spectra (HPLC ES-MS) were obtained using a Hewlett-Packard 1100 HPLC equipped with a quaternary pump, a variable wavelength detector, a C-18 column, and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. Spectra were scanned from 120-800 amu using a variable ion time according to the number of ions in the source. Gas chromatography - ion selective mass spectra (GC-MS) were obtained with a Hewlett Packard 5890 gas chromatograph equipped with an HP-1 methyl silicone column (0.33 mM coating; 25 m x 0.2 mm) and a Hewlett Packard 5971 Mass Selective Detector (ionization energy 70 eV).

Elemental analyses were conducted by Robertson Microlit Labs, Madison NJ. All ureas displayed NMR spectra, LRMS and either elemental analysis or HRMS consistent with assigned structures.


List of Abbreviations and Acronyms:

AcOH	acetic acid
anh	anhydrous
BOC	<i>tert</i> -butoxycarbonyl
conc	concentrated
dec	decomposition
DMPU	1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone

	DMF	<i>N,N</i> -dimethylformamide
	DMSO	dimethylsulfoxide
	DPPA	diphenylphosphoryl azide
	EtOAc	ethyl acetate
5	EtOH	ethanol (100%)
	Et ₂ O	diethyl ether
	Et ₃ N	triethylamine
	<i>m</i> -CPBA	3-chloroperoxybenzoic acid
	MeOH	methanol
10	pet. ether	petroleum ether (boiling range 30-60 °C)
	THF	tetrahydrofuran
	TFA	trifluoroacetic acid
	Tf	trifluoromethanesulfonyl

15 A. General Methods for Synthesis of Heterocyclic Amines


A1. General Procedure for the Preparation of *N*¹-Aryl-5-aminopyrazoles




***N*¹-(4-Methoxyphenyl)-5-amino-3-*tert*-butylpyrazole:** A mixture of 4-methoxyphenylhydrazine hydrochloride (3.5 g), 4,4-dimethyl-3-oxopentanenitrile (2.5 g), EtOH (30 mL), and AcOH (1 mL) was heated at the reflux temperature for 3 h, cooled to room temp., and poured into a mixture of Et₂O (100 mL) and a 10% Na₂CO₃ solution (100 mL). The organic layer was washed with a saturated NaCl solution, dried (MgSO₄) and concentrated under reduced pressure. The solid residue was washed with pentane to afford the desired pyrazole as a pale brown solid. (4.25g):

25 ¹H-NMR (DMSO-*d*₆) δ 1.18 (s, 9H); 3.78 (s, 3H); 5.02 (br s, 2H); 5.34 (s, 1H); 6.99 (d, *J*=8 Hz, 2H); 7.42 (d, *J*=8 Hz, 2H).

A2. General Method for the Mitsunobu-Based Synthesis of 2-Aryl-3-aminofurans




Step 1. 4,4-Dimethyl-3-(4-pyridinylmethoxy)-2-pentenitrile: A solution of triphenylphosphine (2.93 g, 11.2 mmol) in anhyd THF (50 mL) was treated with diethyl azodicarboxylate (1.95 g, 11.2 mmol) and 4-pyridinylmethanol (1.22 g, 11.2 mmol), then stirred for 15 min. The resulting white slurry was treated with 4,4-dimethyl-3-oxopentenenitrile (1.00 g, 7.99 mmol), then stirred for 15 min. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (30% EtOAc/70% hexane) to give the desired nitrile as a yellow solid (1.83 g, 76%): TLC (20% EtOAc/80% hexane) R_f 0.13; $^1\text{H-NMR}$ (CDCl_3) δ 1.13 (s, 9H), 4.60 (s, 1H), 5.51 (s, 2H), 7.27 (d, $J=5.88$ Hz, 2H), 8.60 (d, $J=6.25$ Hz, 2H); $^{13}\text{C-NMR}$ (CDCl_3) δ 27.9 (3C), 38.2, 67.5, 70.8, 117.6, 121.2 (2C), 144.5, 149.9 (2C), 180.7; CI-MS m/z (rel abundance) 217 ($(\text{M}+\text{H})^+$, 100%).




Step 2. 3-Amino-2-(4-pyridinyl)-5-tert-butylfuran: A solution of 4,4-dimethyl-3-(4-pyridinylmethoxy)-2-pentenitrile (1.55 g, 7.14 mmol) in anhyd DMSO (75 mL) was treated with potassium *tert*-butoxide (0.88 g, 7.86 mmol) and stirred at room temp for 10 min. The resulting mixture was treated with EtOAc (300 mL), then sequentially washed with water (2 x 200 mL) and a saturated NaCl solution (100 mL). Combined aqueous phases were back-extracted with EtOAc (100 mL). The combined organic phases were dried (Na_2SO_4) and concentrated under reduced pressure. The residue was purified by column chromatography (gradient from 30% EtOAc/70% hexane to 100% EtOAc) to give the desired product as an orange oil (0.88 g, 57%): TLC (40% EtOAc/60% hexane) R_f 0.09; $^1\text{H-NMR}$ (CDCl_3) δ 1.28 (s, 9H), 3.65 (br s,

2H), 5.79 (s, 1H), 7.30 (d, $J=6.25$ Hz, 2H), 8.47 (d, $J=6.25$ Hz, 2H); EI-MS m/z (rel abundance) 216 (M^+ , 30%).

A3. Synthesis 3-Amino-5-alkylthiophenes from *N*-BOC 3-Amino-5-alkyl-2-thiophenecarboxylate esters




Step 1. Methyl 3-(*tert*-Butoxycarbonylamino)-5-*tert*-butyl-2-thiophenecarboxylate: To a solution of methyl 3-amino-5-*tert*-butyl-2-thiophenecarboxylate (150 g, 0.70 mol) in pyridine (2.8 L) at 5 °C was added di-*tert*-butyl dicarbonate (171.08 g, 0.78 mol, 1.1 equiv) and *N,N*-dimethylaminopyridine (86 g, 0.70 mol, 1.00 equiv) and the resulting mixture was stirred at room temp for 7 d. The resulting dark solution was concentrated under reduced pressure (approximately 0.4 mmHg) at approximately 20 °C. The resulting red solids were dissolved in CH_2Cl_2 (3 L) and sequentially washed with a 1 M H_3PO_4 solution (2 x 750 mL), a saturated NaHCO_3 solution (800 mL) and a saturated NaCl solution (2 x 800 mL), dried (Na_2SO_4) and concentrated under reduced pressure. The resulting orange solids were dissolved in abs. EtOH (2 L) by warming to 49 °C, then treated with water (500 mL) to afford the desired product as an off-white solid (163 g, 74%): ^1H -NMR (CDCl_3) δ 1.38 (s, 9H), 1.51 (s, 9H), 3.84 (s, 3H), 7.68 (s, 1H), 9.35 (br s, 1H); FAB-MS m/z (rel abundance) 314 ($(M+H)^+$, 45%).



Step 2. 3-(*tert*-Butoxycarbonylamino)-5-*tert*-butyl-2-thiophenecarboxylic Acid:


To a solution of methyl 3-(*tert*-butoxycarbonylamino)-5-*tert*-butyl-2-thiophenecarboxylate (90.0 g, 0.287 mol) in THF (630 mL) and MeOH (630 mL) was added a solution of NaOH (42.5 g, 1.06 mL) in water (630 mL). The resulting mixture was heated at 60 °C for 2 h, concentrated to approximately 700 mL under reduced pressure, and cooled to 0 °C. The pH was adjusted to approximately 7 with a 1.0 N HCl solution (approximately 1 L) while maintaining the internal temperature at approximately 0 °C. The resulting mixture was treated with EtOAc (4 L). The pH was adjusted to approximately 2 with a 1.0 N HCl solution (500 mL). The organic phase was washed with a saturated NaCl solution (4 x 1.5 L), dried (Na₂SO₄), and concentrated to approximately 200 mL under reduced pressure. The residue was treated with hexane (1 L) to form a light pink (41.6 g). Resubmission of the mother liquor to the concentration-precipitation protocol afforded additional product (38.4 g, 93% total yield): ¹H-NMR (CDCl₃) δ 1.94 (s, 9H), 1.54 (s, 9H), 7.73 (s, 1H), 9.19 (br s, 1H); FAB-MS *m/z* (rel abundance) 300 ((M+H)⁺, 50%).



Step 3. 5-*tert*-Butyl-3-thiopheneammonium Chloride: A solution of 3-(*tert*-butoxycarbonylamino)-5-*tert*-butyl-2-thiophenecarboxylic acid (3.0 g, 0.010 mol) in dioxane (20 mL) was treated with an HCl solution (4.0 M in dioxane, 12.5 mL, 0.050 mol, 5.0 equiv), and the resulting mixture was heated at 80 °C for 2 h. The resulting cloudy solution was allowed to cool to room temp forming some precipitate. The slurry was diluted with EtOAc (50 mL) and cooled to -20 °C. The resulting solids were collected and dried overnight under reduced pressure to give the desired salt as an off-white solid (1.72 g, 90%): ¹H-NMR (DMSO-d₆) δ 1.31 (s, 9H), 6.84 (d, *J*=1.48 Hz, 1H), 7.31 (d, *J*=1.47 Hz, 1H), 10.27 (br s, 3H).

B. General Methods for Synthesis of Substituted Anilines


B1. General Method for Substituted Aniline Synthesis via Nucleophilic Aromatic Substitution using a Halopyridine



- 5 **3-(4-Pyridinylthio)aniline:** To a solution of 3-aminothiophenol (3.8 mL, 34 mmol) in anhyd DMF (90 mL) was added 4-chloropyridine hydrochloride (5.4 g, 35.6 mmol) followed by K_2CO_3 (16.7 g, 121 mmol). The reaction mixture was stirred at room temp. for 1.5 h, then diluted with EtOAc (100 mL) and water (100 mL). The aqueous layer was back-extracted with EtOAc (2 x 100 mL). The combined organic layers
- 10 were washed with a saturated NaCl solution (100 mL), dried ($MgSO_4$), and concentrated under reduced pressure. The residue was filtered through a pad of silica (gradient from 50% EtOAc/50% hexane to 70% EtOAc/30% hexane) and the resulting material was triturated with a Et_2O /hexane solution to afford the desired product (4.6 g, 66%): TLC (100 % ethyl acetate) R_f 0.29; 1H -NMR ($DMSO-d_6$) δ 5.41
- 15 (s, 2H), 6.64-6.74 (m, 3H), 7.01 (d, $J=4.8$, 2H), 7.14 (t, $J=7.8$ Hz, 1H), 8.32 (d, $J=4.8$, 2H).

C. General Methods of Urea Formation

C1a. Reaction of a Heterocyclic Amine with an Aryl Isocyanate




20

N-(1-(4-Methoxyphenyl)-3-tert-butyl-5-pyrazolyl)-N'-(2,3-dichlorophenyl)urea:

- To a stirring solution of 1-(4-methoxyphenyl)-3-tert-butyl-5-aminopyrazole (0.342 g, 1.39 mmol) in anhyd toluene (9 mL) was added 2,3-dichlorophenyl isocyanate (0.276 mL, 2.09 mmol). The solution was sealed and stirred in the dark for 96 h at 60 °C.
- 25 After this time, the reaction mixture was diluted with EtOAc (200 mL). The resulting

mixture was sequentially washed with a 1 M HCl solution (2 x 125 mL) and a saturated NaCl solution (50 mL), dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by column chromatography (20% EtOAc/80% hexane) to give the product as a white solid (0.335 g, 56%): TLC (20% EtOAc/80% hexane) *R_f* 0.22; ¹H NMR (DMSO-*d*₆) δ 1.24 (s, 9H), 3.79 (s, 3H), 6.33 (s, 1H), 7.05 (d, *J*=9 Hz, 2H), 7.28 (m, 2H), 7.38 (d, *J*=9 Hz, 2H), 8.05 (dd, *J*=3, 6 Hz, 1H), 8.75 (s, 1H), 9.12 (s, 1H); FAB-MS *m/z* 433 ((*M*+*H*)⁺).


C1b. Reaction of a Heterocyclic Amine with an Aryl Isocyanate




10

N-(2-(4-Pyridinyl)-5-*tert*-butyl-3-furyl)-*N'*-(2,3-dichlorophenyl)urea: A solution of 3-amino-2-(4-pyridinyl)-5-*tert*-butylfuran (Method A2; 0.10 g, 0.46 mmol) and 2,3-dichlorophenyl isocyanate (0.13 g, 0.69 mmol) in CH₂Cl₂ was stirred at room temp. for 2 h, then was treated with 2-(dimethylamino)ethylamine (0.081 g, 0.92 mmol) and stirred for an additional 30 min. The resulting mixture was diluted with EtOAc (50 mL), then was sequentially washed with a 1 N HCl solution (50 mL), a saturated NaHCO₃ solution (50 mL) and a saturated NaCl solution (50 mL), dried (Na₂SO₄), and concentrated under reduced pressure. The residue was purified using column chromatography (gradient from 10% EtOAc/90% hexane to 40% EtOAc/60% hexane) to give the desired compound as a white solid (0.12 g, 63%): mp 195-198 °C; TLC (60% EtOAc/40% hexane) *R_f* 0.47; ¹H NMR (DMSO-*d*₆) δ 1.30 (s, 9H); 6.63 (s, 1H); 7.30-7.32 (m, 2H), 7.58 (dm, *J*=6.62 Hz, 2H), 8.16 (dd, *J*=2.57, 6.99 Hz, 1H), 8.60 (dm, *J*=6.25 Hz, 2H), 8.83 (s, 1H), 9.17 (s, 1H); ¹³C NMR (DMSO-*d*₆) δ 28.5 (3C), 32.5, 103.7, 117.3 (2C), 119.8, 120.4, 123.7, 125.6, 128.1, 131.6, 135.7, 136.5, 137.9, 150.0 (2C), 152.2, 163.5; CI-MS *m/z* (rel abundance) 404 ((*M*+*H*)⁺, 15%), 406 ((*M*+*H*+2)⁺, 8%).

25

C1c. Reaction of a Heterocyclic Amine with an Isocyanate

***N*-(5-*tert*-Butyl-3-thienyl)-*N'*-(2,3-dichlorophenyl)urea:** Pyridine (0.163 mL, 2.02 mmol) was added to a slurry of 5-*tert*-butylthiopheneammonium chloride (Method A4c; 0.30 g, 1.56 mmol) and 2,3-dichlorophenyl isocyanate (0.32 mL, 2.02 mmol) in CH₂Cl₂ (10 mL) to clarify the mixture and the resulting solution was stirred at room temp. overnight. The reaction mixture was then concentrated under reduced pressure and the residue was separated between EtOAc (15 mL) and water (15 mL). The organic layer was sequentially washed with a saturated NaHCO₃ solution (15 mL), a 1N HCl solution (15 mL) and a saturated NaCl solution (15 mL), dried (Na₂SO₄), and concentrated under reduced pressure. A portion of the residue was by preparative HPLC (C-18 column; 60% acetonitrile/40% water/0.05% TFA) to give the desired urea (0.180 g, 34%): mp 169-170 °C; TLC (20% EtOAc/80% hexane) *R_f* 0.57; ¹H-NMR (DMSO-*d*₆) δ 1.31 (s, 9H), 6.79 (s, 1H), 7.03 (s, 1H), 7.24-7.33 (m, 2H), 8.16 (dd, *J*=1.84, 7.72 Hz, 1H), 8.35 (s, 1H), 9.60 (s, 1H); ¹³C-NMR (DMSO-*d*₆) δ 31.9 (3C), 34.0, 103.4, 116.1, 119.3, 120.0, 123.4, 128.1, 131.6, 135.6, 138.1, 151.7, 155.2; FAB-MS *m/z* (rel abundance) 343 ((*M*+*H*)⁺, 83%), 345 ((*M*+*H*+2)⁺, 56%), 347 ((*M*+*H*+4)⁺, 12%).


C20 Reaction of Substituted Aniline with *N,N'*-Carbonyldiimidazole Followed by Reaction with a Heterocyclic Amine

***N*-(1-Phenyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinylmethyl)phenyl)urea:** A solution of 4-(4-pyridinylmethyl)aniline (0.25 g, 1.38 mmol) and *N,N'*-

carbonyldiimidazole (0.23 g, 1.42 mmol) in CH₂Cl₂ 11 mL) at room temp. was stirred for 2 h, then treated with 5-amino-1-phenyl-3-*tert*-butyl-5-pyrazole (0.30 g, 1.38 mmol) and the resulting mixture was stirred at 50 °C overnight. The reaction mixture was diluted with EtOAc (25 mL), then sequentially washed with water (30 mL) and a saturated NaCl solution (30 mL), dried (MgSO₄), and concentrated under reduced pressure. The residue was purified by column chromatography (gradient from 100% CH₂Cl₂ to 30% acetone/70% CH₂Cl₂) and the resulting material was recrystallized (EtOAc/Et₂O) to give the desired product complexed with 0.25 equiv H₂O (0.30 g): TLC (60% acetone/40% CH₂Cl₂) R_f 0.56; ¹H-NMR (DMSO-d₆) δ 1.25 (s, 9H); 3.86 (s, 2H), 6.34 (s, 1H), 7.11 (d, *J*=8.82 Hz, 2H), 7.19 (dm, *J*=6.25 Hz, 2H), 7.31 (d, *J*=1.84 Hz, 2H), 7.35-7.51 (m, 5 H), 8.34 (s, 1H), 8.42 (dm, *J*=5.98 Hz, 2H), 8.95 (s, 1H); FAB-MS *m/z* (rel abundance) 426 ((M+H)⁺, 100%).

D. Interconversion of Ureas


15 D1. General Method for Electrophilic Halogenation of Aryl Ureas



***N*-(2-Bromo-5-*tert*-butyl-3-thienyl)-*N'*-(2,3-dichlorophenyl)urea:** To a slurry of *N*-(5-*tert*-butyl-3-thienyl)-*N'*-(2,3-dichlorophenyl)urea (Method C1c; 3.00 g, 8.74 mmol) in CHCl₃ (200 mL) at room temp was slowly added a solution of Br₂ (0.46 mL, 1.7 mmol) in CHCl₃ (150 mL) via addition funnel over 2.5 h, causing the reaction mixture to become homogeneous. Stirring was continued 20 min after which TLC analysis indicated complete reaction. The reaction mixture was concentrated under reduced pressure, and the residue triturated (Et₂O/hexane) and the resulting solids were washed (hexane) to give the brominated product as a pink powder (3.45 g, 93%); mp 180-183 °C; TLC (10% EtOAc/90% hexane) R_f 0.68; ¹H NMR (DMSO-d₆) δ 1.28 (s, 9H), 7.27-7.31 (m, 2H), 7.33 (s, 1H), 8.11 (dd, *J*=3.3, 6.6 Hz, 1H), 8.95 (s, 1H), 9.12 (s, 1H); ¹³C NMR (DMSO-d₆) δ 31.5 (3C), 34.7, 91.1, 117.9, 120.1, 120.5,


123.8, 128.0, 131.6, 135.5, 137.9, 151.6, 155.3; FAB-MS m/z (rel abundance) 421 ((M+H)⁺, 7%), 423 (M+2+H)⁺, 10%).

D2. General Method for Metal-Mediated Cross-Coupling Reactions with Halogen-Substituted Ureas



***N*-(2-Phenyl-5-*tert*-butyl-3-thienyl)-*N'*-(2,3-dichlorophenyl)urea:** To a solution of *N*-(3-(2-bromo-5-*tert*-butylthienyl)-*N'*-(2,3-dichlorophenyl)urea (0.50 g, 1.18 mmol) and phenyltrimethyltin (0.21 mL, 1.18 mmol) in DMF (15 mL) was added Pd(PPh₃)₂Cl₂ (0.082 g, 0.12 mmol), and the resulting suspension was heated at 80 °C overnight. The reaction mixture was diluted with EtOAc (50 mL) and water (50 mL), and the organic layer sequentially washed with water (3 x 50 mL) and a saturated NaCl solution (50 mL), then dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by MPLC (Biotage®; gradient from 100% hexane to 5% EtOAc/95% hexane) followed by preparative HPLC (C-18 column; 70% CH₃CN/30% water/0.05% TFA). The HPLC fractions were concentrated under reduced pressure and the resulting aqueous mixture was extracted with EtOAc (2 x 50 mL). The combined organic layers were dried (Na₂SO₄) and concentrated under reduced pressure to give a gummy semi-solid, which was triturated with hexane to afford the desired product as a white solid (0.050 g, 10%): mp 171-173 °C; TLC (5% EtOAc/95% hexane) R_f 0.25; ¹H NMR (CDCl₃) δ 1.42 (s, 9H), 6.48 (br s, 1H), 7.01 (s, 1H), 7.10-7.18 (m, 2H), 7.26-7.30 (m, 1H), 7.36 (app t, J =7.72 Hz, 2H), 7.39 (br s, 1H), 7.50 (dm, J =6.99 Hz, 2H), 7.16 (dd, J =2.20, 7.72 Hz, 1H); ¹³C NMR (CDCl₃) δ 32.1 (3C), 34.8, 118.4, 118.8, 120.7, 121.1, 124.2, 127.7, 127.9, 128.2 (2C), 128.5, 129.0 (2C), 132.4, 132.5, 136.9, 153.1, 156.3; FAB-MS m/z (rel abundance) 419 ((M+H)⁺, 6%), 421 ((M+H+2)⁺, 4%).


D3. General Methods of Reduction of Nitro-Containing Aryl Ureas



N-(1-(3-Aminophenyl)-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinylthio)phenyl)urea:

A solution of *N*-(1-(3-nitrophenyl)-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinylthio)phenyl)urea (Prepared in methods analogous to those described in A1 and C1a; 0.310 g, 0.635 mmol) in acetic acid (20 mL) was placed under an atmosphere of Ar using a vacuum-degassed and argon-purge protocol. To this was added water (0.2 mL) followed by iron powder (325 mesh; 0.354 g, 6.35 mmol). The reaction mixture was stirred vigorously under argon at room temp. for 18 h, at which time TLC indicated the absence of starting material. The reaction mixture was filtered and the solids were washed copiously with water (300 mL). The orange solution was then brought to pH 4.5 by addition of NaOH pellets (a white precipitate forms). The resulting suspension was extracted with Et₂O (3 x 250 mL), and the combined organic layers were washed with a saturated NaHCO₃ solution (2 x 300 mL) until foaming ceased. The resulting solution was dried (MgSO₄) and concentrated under reduced pressure. The resulting white solid was purified by column chromatography (gradient from 30% acetone/70% CH₂Cl₂ to 50% acetone/50% CH₂Cl₂) to give the product as a white solid (0.165 g, 57%): TLC (50% acetone/50% CH₂Cl₂) R_f 0.50; ¹H NMR (DMSO-*d*₆) δ 1.24 (s, 9H), 5.40 (br s, 2H), 6.34 (s, 1H), 6.57 (d, *J*=8 Hz, 2H), 6.67 (s, 1H), 6.94 (d, *J*=6 Hz, 2H), 7.12 (app t, *J*=8 Hz, 1H), 7.47 (d, *J*=9 Hz, 2H), 7.57 (d, *J*=9 Hz, 2H), 8.31 (d, *J*=6 Hz, 2H), 8.43 (s, 1H), 9.39 (s, 1H); FAB-MS *m/z* 459 ((*M*+H)⁺).

**D4. General Methods of Acylation of Amine-Containing Aryl
Ureas**




***N*-(1-(3-Acetamidophenyl)-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-phenoxyphenyl)urea:**

- 5 To a solution of *N*-(1-(3-aminophenyl)-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-phenoxyphenyl)urea (prepared using methods analogous to those described in A1, C1a and D3; 0.154 g, 0.349 mmol) in CH₂Cl₂ (10 mL) was added pyridine (0.05 mL) followed by acetyl chloride (0.030 mL, 0.417 mmol). The reaction mixture was stirred under argon at room temp. for 3 h, at which time TLC analysis indicated the
- 10 absence of starting material. The reaction mixture was diluted with CH₂Cl₂ (20 mL), then the resulting solution was sequentially washed with water (30 mL) and a saturated NaCl solution (30 mL), dried (MgSO₄) and concentrated under reduced pressure. The resulting residue was purified by column chromatography (gradient from 5% EtOAc/95% hexane to 75% EtOAc/25% hexane) to give the product as a
- 15 white solid (0.049 g, 30%): TLC (70% EtOAc/30% hexane) *R_f* 0.32; ¹H NMR (DMSO-*d*₆) δ 1.26 (s, 9H), 2.05 (s, 3H), 6.35 (s, 1H), 6.92-6.97 (m, 4H), 7.05-7.18 (m, 2H), 7.32-7.45 (m, 5H), 7.64-7.73 (m, 2H), 8.38 (s, 1H), 9.00 (s, 1H), 10.16 (s, 1H); FAB-MS *m/z* 484 ((*M*+H)⁺).























The following compounds have been synthesized according to the General Methods listed above:



















Table 1. 2-Substituted-5-*tert*-butylpyrazolyl Ureas



5

Entry	R ¹	R ²	mp (°C)	TLC R _f	Solvent System	Mass Spec. [Source]	Synth. Method
1				0.42	20% EtOAc/ 80% hexane	403 (M+H)+ [FAB]	A1, C1a
2				0.50	67% EtOAc/ 33% hexane	418 (M+H)+ [FAB]	A1, C1a, D3
3				0.27	20% EtOAc/ 80% hexane	417 (M+H)+ [FAB]	A1, C1a
4				0.27	100% EtOAc	421 (M+H)+ [FAB]	A1, C1a
5				0.50	20% EtOAc/ 80% hexane	437 (M+H)+ [FAB]	A1, C1a
6				0.60	50% EtOAc/ 50% hexane	481 (M+H)+ [FAB]	A1, C1a
7				0.37	20% EtOAc/ 80% hexane	448 (M+H)+ [FAB]	A1, C1a
8				0.35	20% EtOAc/ 80% hexane	433 (M+H)+ [FAB]	A1, C1a

9				0.40	20% EtOAc/ 80% hexane	471 (M+H)+ [FAB]	A1, C1a
10				0.22	20% EtOAc/ 80% hexane	433 (M+H)+ [FAB]	A1, C1a
11				0.39	50% EtOAc/ 50% hexane	418 (M+H)+ [FAB]	A1, C1a, D3
12				0.31	30% EtOAc/ 70% hexane	448 (M+H)+ [FAB]	A1, C1a
13			97-100			403 (M+H)+ [FAB]	A1, C1a
14			84-85			371 (M+H)+ [FAB]	A1, C1a
15			156-159			353 (M+H)+ [FAB]	A1, C1a
16			168-169			360 (M+H)+ [FAB]	A1, C1a
17			131-135			380 (M+H)+ [CI]	A1, C1a
18				0.31	70% EtOAc/ 30% hexane	484 (M+H)+ [FAB]	A1, C1a, D3, D4
19				0.14	50% EtOAc/ 50% hexane	442 (M+H)+ [FAB]	A1, C1a, D3

20				0.19	30% EtOAc/ 70% hexane	472 (M+H)+ [FAB]	A1, C1a
21				0.56	60% acetone / 40% CH ₂ Cl ₂	426 (M+H)+ [FAB]	A1, C2
22				0.34	10% MeOH/ 90% CH ₂ Cl ₂	427 (M+H)+ [FAB]	A1, C2
23				0.44	40% acetone / 60% CH ₂ Cl ₂	494 (M+H)+ [FAB]	A1, C2
24				0.44	40% acetone / 60% CH ₂ Cl ₂	444 (M+H)+ [FAB]	A1, C2
25				0.46	40% acetone / 60% CH ₂ Cl ₂	440 (M+H)+ [FAB]	A1, C2
26				0.48	40% acetone / 60% CH ₂ Cl ₂	444 (M+H)+ [FAB]	A1, C2
27				0.34	40% acetone / 60% CH ₂ Cl ₂	504 (M+H)+	A1, C2
28				0.47	40% acetone / 60% CH ₂ Cl ₂	471 (M+H)+ [FAB]	A1, C2



















29				0.51	60% acetone / 40% CH ₂ Cl ₂ 2	456 (M+H)+ [FAB]	A1, C2
30				0.50	50% acetone / 50% CH ₂ Cl ₂ 2	441 (M+H)+ [FAB]	A1, C2, D3
31				0.43	30% acetone / 70% CH ₂ Cl ₂ 2	471 (M+H)+ [FAB]	A1, C2
32				0.50	50% acetone / 50% CH ₂ Cl ₂ 2	459 (M+H)+ [FAB]	A1, C2, D3
33				0.47	30% acetone / 70% CH ₂ Cl ₂ 2	489 (M+H)+ [FAB]	A1, C2
34						461 (M+H)+ [FAB]	A1, C2
35						461 (M+H)+ [FAB]	A1, C2
36						445 (M+H)+ [FAB]	A1, C2
37						445 (M+H)+ [FAB]	A1, C2

Table 2. Additional Ureas

Enrty	R ²	mp (°C)	TLC R _f	Solvent System	Mass Spec. [Source]	Synth. Method
38		195- 198	0.47	60% EtOAc/ 40% hexane	404 (M+H)+ [FAB]	A2, C1b

5

BIOLOGICAL EXAMPLES**P38 Kinase Assay:**

The *in vitro* inhibitory properties of compounds were determined using a p38 kinase inhibition assay. P38 activity was detected using an *in vitro* kinase assay run in 96-well microtiter plates. Recombinant human p38 (0.5 µg/mL) was mixed with substrate (myelin basic protein, 5 µg/mL) in kinase buffer (25 mM Hepes, 20 mM MgCl₂ and 150 mM NaCl) and compound. One µCi/well of ³³P-labeled ATP (10 µM) was added to a final volume of 100 µL. The reaction was run at 32 °C for 30 min. and stopped with a 1M HCl solution. The amount of radioactivity incorporated into the substrate was determined by trapping the labeled substrate onto negatively charged glass fiber filter paper using a 1% phosphoric acid solution and read with a scintillation counter. Negative controls include substrate plus ATP alone.

All compounds exemplified displayed p38 IC₅₀s of between 1 nM and 10 µM.

20

LPS Induced TNFα Production in Mice:

The *in vivo* inhibitory properties of selected compounds were determined using a murine LPS induced TNFα production *in vivo* model. BALB/c mice (Charles River Breeding Laboratories; Kingston, NY) in groups of ten were treated with either vehicle or compound by the route noted. After one hour, endotoxin (E. coli

25

lipopolysaccharide (LPS) 100 μ g) was administered intraperitoneally (i.p.). After 90 min, animals were euthanized by carbon dioxide asphyxiation and plasma was obtained from individual animals by cardiac puncture into heparinized tubes. The samples were clarified by centrifugation at 12,500 x g for 5 min at 4 °C. The
5 supernatants were decanted to new tubes, which were stored as needed at -20 °C. TNF α levels in sera were measured using a commercial murine TNF ELISA kit (Genzyme).

The preceding examples can be repeated with similar success by substituting the
10 generically of specifically described reactants and/or operating conditions of this invention for those used in the preceding examples

From the foregoing discussion, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope
15 thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

5


WHAT IS CLAIMED IS:

1. A method for the treatment of disease other than cancer mediated by



p38 which comprises administering a compound of formula I or a pharmaceutically acceptable salt thereof

- 10 wherein A is a heteroaryl selected from the group consisting of
 wherein R^1 is selected from the group consisting of C_3 - C_{10} alkyl, C_3 - C_{10} cycloalkyl, up to per-halosubstituted C_1 - C_{10} alkyl and up to per-halosubstituted C_3 - C_{10}



cycloalkyl;

- 15 B is a substituted or unsubstituted, up to tricyclic, aryl or heteroaryl moiety of
 up to 30 carbon atoms with at least one 5- or 6-member aromatic structure containing
 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein if B is a
 substituted group, it is substituted by one or more substituents independently selected
 from the group consisting of halogen, up to per-halosubstitution, and X_n ,

- 20 wherein n is 0-3 and each X is independently selected from the group
 consisting of $-\text{CN}$, CO_2R^5 , $-\text{C}(\text{O})\text{NR}^5\text{R}^{5'}$, $-\text{C}(\text{O})\text{R}^5$, $-\text{NO}_2$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NR}^5\text{R}^{5'}$,

-NR⁵C(O)OR^{5'}, -NR⁵C(O)R^{5'}, C₁-C₁₀ alkyl, C₂₋₁₀-alkenyl, C₁₋₁₀-alkoxy, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₇-C₂₄ alkaryl, C₃-C₁₃ heteroaryl, C₄-C₂₃ alkheteroaryl, substituted C₁-C₁₀ alkyl, substituted C₂₋₁₀-alkenyl, substituted C₁₋₁₀-alkoxy, substituted C₃-C₁₀ cycloalkyl, substituted C₄-C₂₃ alkheteroaryl and -Y-Ar;

5 where X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R⁵, -C(O)R⁵, -C(O)NR⁵R^{5'}, -OR⁵, -SR⁵, -NR⁵R^{5'}, -NO₂, -NR⁵C(O)R^{5'}, -NR⁵C(O)OR^{5'} and halogen up to per-halosubstitution;

10 wherein R⁵ and R^{5'} are independently selected from H, C₁-C₁₀ alkyl, C₂₋₁₀-alkenyl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₃-C₁₃ heteroaryl, C₇-C₂₄ alkaryl, C₄-C₂₃ alkheteroaryl, up to per-halosubstituted C₁-C₁₀ alkyl, up to per-halosubstituted C₂₋₁₀-alkenyl, up to per-halosubstituted C₃-C₁₀ cycloalkyl, up to per-halosubstituted C₆-C₁₄ aryl and up to per-halosubstituted C₃-C₁₃ heteroaryl,

15 wherein Y is - O-, -S-, -N(R⁵)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-, -NR⁵C(O)NR⁵R^{5'}-, -NR⁵C(O)-, -C(O)NR⁵-, -(CH₂)_mS-, -(CH₂)_mN(R⁵)-, -O(CH₂)_m-, -CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁵)(CH₂)_m-,

m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by
 20 halogen up to per-halosubstitution and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R⁵, -C(O)NR⁵R^{5'}, -C(O)NR⁵-, -NO₂, -OR⁵, -SR⁵, -NR⁵R^{5'}, -NR⁵C(O)OR^{5'}, -OC(O)R⁵, -NR⁵C(O)R^{5'}, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₃-C₁₃ heteroaryl, C₇-C₂₄ alkaryl, C₄-C₂₃ alkheteroaryl, substituted C₁-C₁₀ alkyl, substituted C₃-C₁₀ cycloalkyl,
 25 substituted C₇-C₂₄ alkaryl and substituted C₄-C₂₃ alkheteroaryl;

wherein if Z is a substituted group, it is substituted by the one or more substituents independently selected from the group consisting of -CN, -CO₂R⁵, -C(O)NR⁵R^{5'}, -OR⁵, -SR⁵, -NO₂, -NR⁵R^{5'}, -NR⁵C(O)R^{5'} and -NR⁵C(O)OR^{5'}, and

30 wherein R² is C₆-C₁₄ aryl, C₃-C₁₄ heteroaryl, substituted C₆-C₁₄ aryl or substituted C₃-C₁₄ heteroaryl,

wherein if R^2 is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and V_n ,


wherein $n = 0-3$ and each V is independently selected from the group consisting of $-CN$, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-C(O)R^5$,
 5 $-OC(O)NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-SO_2R^5$, $-SOR^5$, $-NR^5C(O)R^{5'}$, $-NO_2$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{24} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_6-C_{14} aryl, substituted C_3-C_{13} heteroaryl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{24}
 10 alkheteroaryl,

where V is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, $-CN$, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-NR^5R^{5'}$, $-OR^5$, $-SR^5$,
 $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and $-NO_2$,
 15 wherein R^5 and $R^{5'}$ are each independently as defined above.

2. A method as in claim 1, wherein R^2 is selected from substituted or unsubstituted members of the group consisting of phenyl and pyridinyl, and the substituents for R^2 are selected from the group consisting of halogen, up to per-halosubstitution and Y_n , wherein $n = 0-3$, and each Y is independently selected from the group consisting of substituted and unsubstituted C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, $-NO_2$, $-NH_2$, $-C(O)-C_{1-6}$ alkyl, $-C(O)N-(C_{1-6} \text{ alkyl})_2$, $-C(O)NH-C_{1-6}$ alkyl, $-O-C_{1-6}$ alkyl, $-NHC(O)H$, $-NHC(O)OH$, $-N(C_{1-6} \text{ alkyl})C(O)-C_{1-6}$ alkyl, $-N-(C_{1-6} \text{ alkyl})C(O)-C_{1-6}$ alkyl, $-NHC(O)-C_{1-6}$ alkyl, $-OC(O)NH$ C_{6-14} aryl, $-NHC(O)O-C_{1-6}$ alkyl, $-S(O)-C_{1-6}$ alkyl and $-SO_2-C_{1-6}$ alkyl,

wherein if Y is a substituted group, it is substituted by one or more halogen, up to per-halosubstitution.

3. A method as in claim 1, wherein B is up to a tricyclic aromatic ring structure selected from the group consisting of



which is substituted or unsubstituted by halogen, up to per-halosubstitution, and
5 wherein

$n = 0-3$ and

each X is independently selected from the group consisting of $-CN$, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^{5'}$, C_1-C_{10} alkyl, C_{2-10} -alkenyl, C_{1-10} -alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, and substituted C_1-C_{10} alkyl, substituted C_{2-10} -alkenyl, substituted C_{1-10} -alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_4-C_{23} alkheteroaryl and $-Y-Ar$;

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of $-CN$, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NO_2$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^5$ and halogen up to per-halosubstitution;


wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10} -alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_{2-10} -

alkenyl, up to per-halosubstituted C₃-C₁₀ cycloalkyl, up to per-halosubstituted C₆-C₁₄ aryl and up to per-halosubstituted C₃-C₁₃ heteroaryl,

wherein Y is -O-, -S-, -N(R⁵)-, -(CH₂)_m-, -C(O)-, -CH(OH)-, -(CH₂)_mO-,
 -NR⁵C(O)NR⁵R^{5'}-, -NR⁵C(O)-, -C(O)NR⁵-, -(CH₂)_mS-, -(CH₂)_mN(R⁵)-, -O(CH₂)_m-,
 5 -CHX^a-, -CX^a₂-, -S-(CH₂)_m- and -N(R⁵)(CH₂)_m-,
 m = 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Z_{n1}, wherein n1 is 0 to
 10 3 and each Z is independently selected from the group consisting of -CN, -C(O)R⁵,
 -CO₂R⁵, -C(O)NR⁵R^{5'}-, -C(O)R⁵-, -NO₂-, -OR⁵-, -SR⁵-, -NR⁵R^{5'}-, -NR⁵C(O)OR^{5'}-,
 -NR⁵C(O)R^{5'}-, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₃-C₁₃ heteroaryl, C₇-C₂₄
 alkaryl, C₄-C₂₃ alkheteroaryl, substituted C₁-C₁₀ alkyl, substituted C₃-C₁₀ cycloalkyl,
 substituted C₇-C₂₄ alkaryl and substituted C₄-C₂₃ alkheteroaryl; wherein if Z is a
 15 substituted group, it is substituted by one or more substituents independently selected
 from the group consisting of -CN, -CO₂R⁵-, -C(O)NR⁵R^{5'}-, -OR⁵-, -SR⁵-, -NO₂-, -NR⁵R^{5'}-,
 -NR⁵C(O)R^{5'} and -NR⁵C(O)OR^{5'}.

4. A method of claim 1, wherein B is



20

wherein

Y is selected from the group consisting of -O-, -S-, -CH₂-, -SCH₂-, -CH₂S-,
 -CH(OH)-, -C(O)-, -CX^a₂-, -CX^aH-, -CH₂O- and -OCH₂-,

25 X^a is halogen,

Q is a six member aromatic structure containing 0-2 nitrogen, substituted or
 unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

$s = 0$ or 1 , and

5 X , Z , n and $n1$ are as defined in claim 1.

5. A method as in claim 4, wherein


Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

10 Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo substitution, or $Y-Q^1$ is phthalimidinyl substituted or unsubstituted by halogen up to per-halo substitution, and

15 Z and X are independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1 - C_{10} -alkyl or C_3 - C_{10} -cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3 - C_{10} -alkyl, C_3 - C_6 -cycloalkyl and C_6 - C_{10} -aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

6. A method as in claim 4, wherein Q is phenyl, Q^1 is phenyl or pyridinyl, Y is $-O-$, $-S-$ or $-CH_2-$, and X and Z are independently Cl , F , CF_3 , NO_2 or CN .

7. A method as in claim 1, which comprises administering a compound of one of the formulae or a pharmaceutically acceptable salt thereof:



wherein B and R² are as defined in claim 1.

8. A method as in claim 7, wherein R² is selected from substituted and unsubstituted members of the group consisting of phenyl and pyridinyl, wherein if R² is a substituted group, it is substituted by one or more substituents selected from the group consisting of halogen and W_n, wherein n = 0-3, and W is selected from the group consisting of -NO₂, -C₁₋₃ alkyl, -NH(O)CH₃, -CF₃, -OCH₃, -F, -Cl, -NH₂, -OC(O)NH up to per-halosubstituted phenyl, -SO₂CH₃, pyridinyl, phenyl, up to per-halosubstituted phenyl and C₁-C₆ alkyl substituted phenyl.

9. A method as in claim 1, comprising administering an amount of compound of formula I effective to inhibit p38.

10. A method as in claim 1, wherein the compound of formula I displays p38 activity (IC₅₀) better than 10μM as determined by an in-vitro kinase assay.

11. A method according to claim 1, wherein the disease is mediated by a cytokine or protease regulated by p38.

5 12. A method according to claim 1, wherein R² is t-butyl.

13. A method according to claim 1, comprising administering an amount of a compound of formula I effective to inhibit p38.

10 14. A method according to claim 1, comprising administering an amount of a compound of formula I effective to inhibit production of a disease-mediating cytokine or protease.

15 15. A method according to claim 1, wherein the disease is an inflammatory or immunomodulatory disease.

16. A method according to claim 1, wherein the disease is rheumatoid arthritis, osteoarthritis, osteoporosis, asthma, septic shock, inflammatory bowel disease, or the result of host-versus-graft reactions.

5

Abstract of the Disclosure

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000